You can buy Welidx at the lowest price at Nextgen.ooo online pharmacy. Belzutifan is a hypoxia-inducible factor 2α (HIF-2α) inhibitor used in the treatment of von Hippel-Lindau disease (VHL)-related cancers. The HIF-2α protein was first identified in the 1990s by researchers at the University of Texas Southwestern Medical Center as a key driver of the growth of certain cancers. Initially thought to be untreatable, a binding pocket was eventually discovered in the HIF-2α molecule that allowed compounds to bind to and inhibit these proteins. This discovery led to the initial development of belzutifan (then called PT2977), which was further developed by a subsidiary of Peloton Pharmaceuticals (which itself was eventually acquired by Merck in 2019).
 
Belzutifan inhibits the complex formation of HIF-2α with another transcription factor, HIF-1β, which is a necessary step in its activation — by preventing this complex formation, belzutifan may slow or stop the growth of VHL-associated tumors. Belzutifan received FDA approval for the treatment of certain VHL-associated cancers on August 13, 2021.